INTRODUCTION
============

Valve disease is increasing as a consequence of population ageing. Up to 2% of patients older than 65 years have moderate or severe AS \[[@R1],[@R2]\]. SAVR dates back to 1960. Soon after its introduction it became the standard treatment for severe AS because it showed survival improvement \[[@R3]\]. Unfortunately, up to one-third of patients with severe AS are ineligible for SAVR because of advanced age or multiple comorbidities. Mortality risk associated with SAVR may be assessed using available algorithms. The most validated are the European System for Cardiac Operative Risk Evaluation (EuroSCORE) \[[@R4]\], and the Society of Thoracic Surgeons (STS) score \[[@R5]\]. Defining a high mortality risk for open surgery involves quantitative assessment (*i.e.*, expected mortality \>20% with the EuroSCORE and \>10% with STS score) and qualitative multidisciplinary clinical judgment.

Since its first implementation in humans in 2002 \[[@R6]\], TAVI has increasingly been recognized as a minimally invasive therapeutic option for patients with severe symptomatic AS with high mortality risk for conventional SAVR. Success rates of TAVI are encouraging \[[@R7]\], thus a trend towards its use in a broader patient population may be expected. The two vascular approaches for TAVI are the retrograde transfemoral approach with balloon-expandable valve, and the anterograde transapical approach with self-expandable valve constructed of bovine pericardium on a metal stent. Transapical TAVI requires a small incision in the chest through an intercostal mini-thoracotomy but provides a stable platform for valve implantation due to the shorter distance for approaching the native valve. The apex of the heart is exposed, the prosthetic valve is compressed and placed on a catheter, which is passed through the apex and out across the patient's own aortic valve. A balloon is then used to expand the artificial valve into position.

Despite being minimally invasive TAVI is associated with potentially serious complications. Although a multicentre trial showed similar 1-year survival rates between TAVI and SAVR in high-risk patients with severe AS \[[@R8]\], long-term outcomes have not been assessed.

The incidence of TAVI-PVE (up to 3%) seems to be slightly higher to that of PVE following SAVR (1%) \[[@R7],[@R9]-[@R11]\]. A recent large multicentre registry showed an incidence of TAVI-PVE of 1.1% (23 of 2,133) and 1.98% (6 of 303) after transfemoral and transapical approach, respectively \[[@R10]\]. In the same report the incidence of TAVI-PVE was higher within the first 12 months (80%) suggesting a noso-comial source; in contrast to surgical PVE in which only 38% of cases occur within the first postoperative year \[[@R12]\]. Another clinical study showed that health care acquisition of the infection is more frequent in TAVI-PVE than in SAVR-PVE (71% *versus*36.5%) \[[@R13]\].

In TAVI-PVE classic signs of endocarditis are infrequent and blood cultures are negative in up to 27% of patients \[[@R10]\].

As TAVI can be performed at the catheterization room there is concern about the safety of undertaking this procedure without high-efficiency particulate air (HEPA) filtered laminar airflow. A recent multicentre review showed that 55% of procedures were performed in the catheterization suite, 34% in a hybrid suite, and 11% in a surgical theatre \[[@R10]\]. One retrospective study found that performing TAVI in a catheterization laboratory was not associated with an increased risk of infective complications \[[@R14]\], as it has been described for implantable cardioverter-defibrillators and pacemakers \[[@R15]\]. Nevertheless this must need to be confirmed with prospective studies.

The management of TAVI-PVE has not been well established. There are no guidelines for indications and opportunity of surgical treatment, which is the most difficult decision in patients previously ineligible for open procedure due to a high mortality risk prediction.

Case report
-----------

A 62 years old female with medical history of arterial hypertension, atrial fibrillation, smoking, chronic obstructive pulmonary disease, obesity and bipolar affective disorder was admitted because of severe AS with heart failure. She had an expected mortality of 11.9% on logistic EuroSCORE and 20.5% on STS score. She refused open conventional surgery for valve replacement, thus she underwent transapical TAVI. The procedure was done in the catheterization room, which is not equipped with HEPA filter laminar flow. The intervention was done under strict sterile working conditions. Antibiotic prophylaxis consisted on piperacillin-tazobactam, vancomycin and amikacin.

One week later she presented with pleural empyema and bacteremia due to *Pseudomonas aeruginosa*(susceptible to ciprofloxacin, ceftazidime, cefepime, piperacillintazobactam, amikacin, colistin; and resistant to imipenem and meropenem). This complication was assumed as organ-space surgical site infection (SSI) and the patient was treated with pleural drainage and cefepime for 6 weeks with a favourable clinical outcome. At that time 2 transesophageal echocardiograms (TEE) (one at admission and the second 4 weeks later) were performed with no evidence of vegetation or perivalvular abscess.

Two weeks after completion of the 6-week antibiotic treatment she was readmitted with fever, a new aortic diastolic murmur and signs of peripheral embolism (Fig. **[1](#F1){ref-type="fig"}**). The patient was treated empirically with vancomycin and cefepime. A new TEE showed a periannular abscess (Movie (Supportive/Supplementary Material). *P. aeruginosa*with the same antibiotic resistance phenotype of previous isolation grew in all of 4 blood cultures. Laboratory tests were remarkable for a white blood cells count of 9,400 per mm^3^ (85% neutrophils), haematocrit 34%, haemoglobin 11.3 g/dL, erythrocyte sedimentation rate of 40 mm/hr and C-reactive protein of 205 mg/L. With diagnosis of early (\< 60 days) PVE due to *P. aeruginosa* complicated with periannular abscess an open SAVR was performed despite a logistic EuroSCORE of 78.5% and STS score of 54.9% at that time (Figs. **[2](#F2){ref-type="fig"}**-**[4](#F4){ref-type="fig"}**). Drainage of the abscess and closure of the fistulous tract was performed with replacement of the aortic prosthesis with a homograft. Antimicrobial treatment was switched to piperacillin-tazobactam and amikacin for 2 weeks. She was discharged on ciprofloxacin and cefepime for completing additional 4 weeks as outpatient parenteral antibiotic therapy. After one year of follow up the patient is in good clinical condition with no evidence of infection relapse.

DISCUSSION
==========

AS is the most prevalent valve disease worldwide. TAVI is a novel procedure for high-risk patients suffering from severe AS. Despite being minimally invasive TAVI may have serious complications that differ from those related to SAVR and include vascular injury, stroke, heart block, coronary obstruction, cardiac perforation, paravalvular leak, valve misplacement and PVE. Since only 13 years has elapsed from its first procedure implementation, long-term results regarding patient survival are still lacking. Thus, indication and appropriateness for TAVI should be cautiously individualized and patients must be advised on the possible complications of the technique.

Although during TAVI the heart chambers are not entirely opened and there is no requirement of extracorporeal circulation; the procedure is indicated in elderly or fragile patients. The latter factors may favour infection, including endocarditis. Additionally in most centres, such as ours, the procedure is done in the catheterization room without HEPA laminar flow \[[@R14]\]. Other factors that may favour infection after TAVI are the frequent paravalvular leak owing to imperfections in the anchor of the implanted valve, as well as the space between the bioprosthesis and the native valve cusp; which may serve as *nidus* for pathogen accumulation during transient bacteremia.

TAVI-PVE often present with subtle symptoms probably due to immunosenescence. The presence of fever is less frequent (75%) than in cases of infective endocarditis in the general population (90%) \[[@R16]\]. Non-specific symptoms such as asthenia or weight loss may be the only symptoms in up to one-fifth of the patients \[[@R16]\]. Also, the occurrence of a new regurgitant heart murmur, an important sign for the diagnosis of endocarditis, is less valuable in TAVI patients due to the high rate of residual paravalvular leak that persists following the procedure. Up to 20% of blood cultures are negative. These facts reduce the sensitivity of the Duke criteria leading to diagnostic delay and subsequent worse outcome \[[@R17],[@R18]\]. An autopsy study of 13 patients deceased after TAVI found 3 cases of acute IE (23%); none of them was identified while the patient was alive \[[@R19]\]. It is very important to have a low threshold for investigation of endocarditis to avoid under diagnosis.

TEE findings in TAVI-PVE also differ from those described in PVE, being periannular complications more frequent (39% of TAVI-PVE compared with 30% of SAVR patients). Development of fistula has been described in 16% of TAVI-PVE patients *versus*3% in SAVR-PVE \[[@R13]\]. Additionally TEE may be difficult to interpret in patients with TAVI due to the shadowing effect and reflectance of the prosthetic material (metallic struts that encircle the valve leaflets). Detection of vegetations in the space between prosthetic and native aortic valve (usually calcified) is particularly difficult. Therefore meticulous examination at multiple views is advised. Eventually, other diagnostic modalities such as positron emission tomography-computed tomography could assist the diagnosis \[[@R20]\].

In the case we are reporting, the valve was well positioned with no leaks evidenced by 2 previous TEE performed one month before the diagnosis of PVE.

TAVI-PVE in-hospital mortality is 50% and 1-year mortality is 66% \[[@R16]\]. These outcomes are striking when compared to in-hospital mortality for native valve endocarditis (15%) and SAVR-PVE (40%) \[[@R16]\]. Importantly, in TAVI-PVE poor results are related with conservative treatment highlighting the role open surgery in such patients despite their high surgical risk. In a German series 4 (26.7%) of 15 patients with TAVI-PVE died; 3 of the 4 patients who died had strong indication for surgical therapy (abscesses, fistulas, pseudoaneurysms); nevertheless open-heart surgery was not done owing to the high risk calculated by scores \[[@R21]\].

CONCLUSION
==========

PVE following TAVI is an emerging endovascular infection whose incidence seems to be slightly higher to that of PVE after SAVR. This could reflect the significant frailty of the patients as well as the learning curve in the technique. The particular features of TAVI candidates, as well as the characteristics of transcatheter valve prostheses, including a high amount of metal around the valve leaflets (stent frame), may alter the clinical manifestations, diagnosis and outcome of TAVI-PVE.

Health care acquisition and a distant primary source of infection are frequent in TAVI-PVE, as in the case we report. To the best of our knowledge this is the second report of TAVI-PVE due to *P. aeruginosa,*being the probable source an organ-space SSI. We cannot exclude the presence of PVE at the first manifestation of bacteremia accompanying the empyema, as TEE can have difficulties for detecting small vegetations in patients with TAVI because of the structure of the prosthetic valve and the calcification of the native valve that remains *in situ*.

The management of TAVI associated PVE is challenging especially when surgery is advised, as in the case of infection due to *P. aeruginosa*, because it occurs in patients previously considered inoperable. Nonetheless surgery seems to be associated with better outcome. Currently, the diagnosis, prevention and management of TAVI-PVE are based on clinical judgment guided by existing guidelines for PVE.

There are some pending questions that need to be resolved by further prospective studies. The safety of doing TAVI procedure in the catheterization room without HEPA laminar flow must be carefully assessed. Until more data are available it seems prudent to perform this procedure in hybrid surgery rooms with laminar flow. Probably preventive measures before TAVI procedure should be the same as with SAVR, including eradication of distant infectious sources (*i.e.* bacteriuria, cutaneous or dental infections), screening and treatment of nasal carriers of *S. aureus*, and timely antibiotic prophylaxis. Diagnostic criteria for TAVI-PVE must be specifically assessed by prospective clinical studies.

As experience grows it becomes clear that TAVI-PVE is an entity requiring specific considerations regarding diagnosis, prevention and treatment.
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